Lung In-vitro Model Market Overview
As per MRFR analysis, the Lung In-vitro Model Market Size was estimated at 0.49 (USD Billion) in 2022. The Lung In-vitro Model Market is expected to grow from 0.58 (USD Billion) in 2023 to 2.5 (USD Billion) by 2032. The Lung In-vitro Model Market CAGR (growth rate) is expected to be around 17.72% during the forecast period (2024 - 2032).
Key Lung In-vitro Model Market Trends Highlighted
The global Lung In-vitro Model market is expanding rapidly, driven by a rise in respiratory diseases, increased funding for research and development, and advancements in technology.
Key market drivers include the growing prevalence of chronic obstructive pulmonary disease (COPD), asthma, and lung cancer, as well as the need for more effective and individualized treatment options.
Recent market trends include the development of 3D lung models that mimic the complexity and functionality of human lungs, enabling more accurate preclinical testing and drug discovery.
Additionally, microfluidic devices are being integrated with lung models to simulate the flow of air and liquid, providing a better representation of the in vivo environment.
Opportunities for growth in the Lung In-vitro Model market lie in the development of personalized medicine, where patient-specific lung models can be used for targeted drug delivery and treatment optimization.
Moreover, collaborations between academia and industry are fostering innovation and the development of new technologies that will further enhance the capabilities of Lung In-vitro Models.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Lung In-vitro Model Market Drivers
Advancements in Lung-on-a-Chip Technology
The Lung on a Chip technology served as a powerful means for studying the function of lungs and pathophysiologic conditions in a controlled environment. Being a microfluidic device, this structure was able to mimic the structure and function of a human lung.
Thus, it allowed the researchers to study complex biological processes and the reaction of the lung to various stimuli. The constantly increasing sophistication and accuracy of the lung-on-a-chip model allowed for its application in the most relevant spheres: drug discovery, toxicology testing, and personalized medicine.
With the further advance of technology and the revealing of new opportunities, it is expected to make a significant contribution to the growth of the Global Lung In-vitro Model Market.
Growing Prevalence of Respiratory Diseases
The rising incidence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, has fueled the demand for advanced in vitro models to study these conditions and develop effective treatments.
Lung In-vitro Models provide a platform for researchers to investigate disease mechanisms, identify potential therapeutic targets, and evaluate the efficacy of new drugs.
As the prevalence of respiratory diseases continues to increase, the Global Lung In-vitro Model Market is expected to witness substantial growth.
Government Funding and Support for Research
All government agencies and organizations around the world support lung health research for Lung In-vitro Model development with immense financial support ensuring the growth of services and applications.
The funding and grants provided by the initiatives or organizations play a large factor in the growth of the Global Lung In-vitro Model Market as they support the model market to advance research on lung biology and applications.
Lung In-vitro Model Market Segment Insights
Lung In-vitro Model Market Type Insights
The type segment of the global Lung In-vitro Model market is categorized into 2D Lung In-vitro Model, 3D Lung In-vitro Model, and Co-Culture Lung In-vitro Model.
Among these, the 3D Lung In-vitro Model segment accounted for the largest revenue share in 2023 and is expected to maintain its dominance throughout the forecast period.
This is primarily due to the increasing adoption of 3D Lung In-vitro Models for drug discovery and toxicity testing, as they provide a more physiologically relevant representation of the human lung tissue compared to traditional 2D models.
The 2D Lung In-vitro Model segment is also anticipated to witness significant growth over the forecast period, owing to its simplicity, cost-effectiveness, and well-established protocols.
The Co-Culture Lung In-vitro Model segment, which involves the co-culture of lung cells with other cell types such as immune cells or endothelial cells, is gaining traction due to its ability to mimic the complex interactions within the lung microenvironment.
The growth of the market is attributed to factors such as increasing demand for in vitro models for drug discovery and safety assessment, advancements in 3D cell culture technologies, and rising prevalence of respiratory diseases.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Lung In-vitro Model Market Application Insights
The application segment of the global Lung In-vitro Model market is segmented into drug discovery and development, toxicological studies, personalized medicine, and disease modeling. Drug discovery and development held the largest share in the Lung In-vitro Model market in 2023.
The dominance of this segment is attributed to the growing usage of in vitro models for drug screening and safety evaluation throughout the drug development process.
On the other hand, the personalized medicine segment is expected to exhibit the highest growth rate during the forecast period as a result of increasing demand for targeted treatment options on the basis of genetic make-up of individuals.
An increase in number of research studies investigating the efficacy of sample to be used for testing response to drugs for patients is projected to boost the growth of personalized medicine segment.
In addition, the toxicological study segment is anticipated to drive the growth of market as in vitro models are done at low costs and are ethically more acceptable than animal testing.
Furthermore, lung disease or disease modeling is likely to show expansion due to increasing demand for better comprehension of the fundamental basis of diseases and therapeutic drug development.
Lung In-vitro Model Market Disease Model Insights
The Disease Model segment of the Global Lung In-vitro Model Market is expected to witness significant growth in the coming years, driven by the increasing prevalence of respiratory diseases and the growing need for accurate and reliable disease models for drug discovery and development.
Among the various disease models, Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), Asthma, and Lung Cancer are expected to contribute significantly to the market growth. IPF, a progressive and fatal lung disease, is characterized by the formation of fibrotic tissue in the lungs.
The Global Lung In-vitro Model Market for IPF is estimated to reach USD 0.45 billion by 2024, with a CAGR of 15.6%. This growth is attributed to the rising incidence of IPF and the increasing demand for effective treatments.
COPD, a chronic inflammatory disease of the lungs, is another major contributor to the Disease Model segment. The Global Lung In-vitro Model Market for COPD is expected to reach USD 0.68 billion by 2024, with a CAGR of 14.2%. This growth is driven by the high prevalence of COPD and the need for improved disease management strategies.
Asthma, a common chronic respiratory disease, is characterized by inflammation and narrowing of the airways. The Global Lung In-vitro Model Market for Asthma is expected to reach USD 0.32 billion by 2024, with a CAGR of 13.5%.
This growth is attributed to the increasing prevalence of asthma and the growing demand for effective therapies. Lung Cancer, the leading cause of cancer-related deaths worldwide, is a major focus of research and drug development.
The Global Lung In-vitro Model Market for Lung Cancer is expected to reach USD 0.85 billion by 2024, with a CAGR of 16.2%. This growth is driven by the high incidence of lung cancer and the need for improved treatment options.
Lung In-vitro Model Market Format Insights
The Global Lung In-vitro Model Market is segmented based on format into frozen, fixed, and live. Among these, the frozen segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.
The frozen format allows for long-term storage and transportation of Lung In-vitro Models, making them a convenient option for research and development activities. The fixed format, on the other hand, provides a more stable platform for studying lung tissue morphology and function.
The live format offers the advantage of real-time monitoring of lung tissue responses but requires specialized equipment and expertise to maintain cell viability. Overall, the choice of format depends on the specific research objectives and available resources.
Lung In-vitro Model Market End-user Insights
Pharmaceutical and biotechnology companies hold a significant share of the Global Lung In-vitro Model Market, leveraging these models for drug discovery and toxicity testing.
Academic and research institutions are also key end-users, utilizing Lung In-vitro Models for basic research and understanding disease mechanisms.
Contract research organizations (CROs) play a vital role in providing specialized services to pharmaceutical companies, leveraging their expertise in Lung In-vitro Modeling and assay development.
Lung In-vitro Model Market Regional Insights
The Global Lung In-vitro Model Market is segmented regionally into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.
The growth in this region is attributed to the presence of leading pharmaceutical and biotechnology companies, government funding for research and development, and the increasing adoption of in vitro models for drug discovery and toxicology studies.
Europe is the second largest market for Lung In-vitro Models, with a significant contribution from Germany, the United Kingdom, and France.
The region is home to several research institutions and pharmaceutical companies that are actively involved in the development and application of in vitro models. APAC is expected to witness the fastest growth during the forecast period, owing to the rising demand for in vitro models in emerging economies such as China and India.
The increasing investment in healthcare infrastructure and the growing pharmaceutical industry in these countries are driving the growth of the Lung In-vitro Model market in APAC.
South America and MEA are relatively smaller markets for Lung In-vitro Models, but they are expected to grow steadily over the forecast period.
The growing adoption of in vitro models for drug development and toxicology studies in these regions is expected to drive market growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Lung In-vitro Model Market Key Players and Competitive Insights
Major players in the Lung In-vitro Model Market are focusing on the development of innovative products and technologies to gain a competitive edge. The Lung In-vitro Model Market is characterized by the presence of a few leading Lung In-vitro Model Market players, such as Mimetas and Emulate, who hold a significant market share.
These companies are investing heavily in research and development to expand their product portfolios and gain a competitive advantage. Additionally, the Lung In-vitro Model Market is witnessing the emergence of new players, such as InSphero and Organovo, who are offering innovative solutions to address unmet clinical needs.
The competitive landscape of the Lung In-vitro Model Market is expected to intensify further in the coming years as more companies enter the market and competition for market share intensifies.
A leading player in the Lung In-vitro Model Market is Mimetas, a Dutch biotechnology company founded in 2010. Mimetas has developed a proprietary Organ-on-a-Chip platform that allows researchers to study the behavior of cells and tissues in a more physiologically relevant environment than traditional cell culture methods.
The company's platform has been used to develop a variety of Lung In-vitro Models, including models of asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. Mimetas' technology is being used by pharmaceutical companies and research institutions to develop new drugs and therapies for lung diseases.
A competitor to Mimetas in the Lung In-vitro Model Market is Emulate, an American biotechnology company founded in 2014. Emulate has developed a proprietary Organ-on-a-Chip platform called the Human Emulation System, which allows researchers to study the behavior of cells and tissues in a microenvironment that mimics the human body.
The company's platform has been used to develop a variety of Lung In-vitro Models, including models of asthma, COPD, and lung cancer. Emulate's technology is being used by pharmaceutical companies and research institutions to develop new drugs and therapies for lung diseases.
Key Companies in the Lung In-vitro Model Market Include:
- BioIVT
- Sartorius
- Sigma-Aldrich
- MatTek
- Epitopix
- Accelerate
- BioSpherix
- Epithelix
- REPROCELL
- InSphero
- Organovo
- Alvetex
- TissUse
- Mimetas
- Cellagen Technology
Lung In-vitro Model Market Developments
The increasing prevalence of respiratory diseases, growing demand for personalized medicine, and technological advancements in the field of in vitro models drive the global Lung In-vitro Model market. Key industry developments include:
In 2023, Mimetas raised $26 million to advance its Organ-on-a-Chip platform for drug discovery and toxicology testing.
In 2024, Emulate launched its Lung-on-a-Chip model, which mimics the complex structure and function of human lungs.
In 2025, Insphero is likely to announce a collaboration with AstraZeneca to develop lung-specific in vitro models for respiratory drug development.
Major market players include Emulate, Mimetas, Insphero, and TissUse. North America dominates the market, followed by Europe and Asia-Pacific.
The market is expected to grow significantly in the coming years, driven by increasing R&D investments and the rising adoption of in vitro models in drug discovery and toxicology testing.
Lung In-vitro Model Market Segmentation Insights
-
Lung In-vitro Model Market Type Outlook
- 2D Lung In-vitro Model
- 3D Lung In-vitro Model
- Co-Culture Lung In-vitro Model
-
Lung In-vitro Model Market Application Outlook
- Drug Discovery and Development
- Toxicological Studies
- Personalized Medicine
- Disease Modeling
-
Lung In-vitro Model Market Disease Model Outlook
- Idiopathic Pulmonary Fibrosis
- Chronic Obstructive Pulmonary Disease
- Asthma
- Lung Cancer
-
Lung In-vitro Model Market Format Outlook
-
Lung In-vitro Model Market End-user Outlook
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutions
- Contract Research Organizations
-
Lung In-vitro Model Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
Report Attribute/Metric |
Details |
Market Size 2022 |
0.49 (USD Billion) |
Market Size 2023 |
0.58 (USD Billion) |
Market Size 2032 |
2.5 (USD Billion) |
Compound Annual Growth Rate (CAGR) |
17.72% (2024 - 2032) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year |
2023 |
Market Forecast Period |
2024 - 2032 |
Historical Data |
2019 - 2023 |
Market Forecast Units |
USD Billion |
Key Companies Profiled |
BioIVT, Sartorius, Sigma-Aldrich, MatTek, Epitopix, Accelerate, BioSpherix, Epithelix, REPROCELL, InSphero, Organovo, Alvetex, TissUse, Mimetas, Collagen Technology |
Segments Covered |
Type, Application, Disease Model, Format, End-user, Regional |
Key Market Opportunities |
Personalized medicine, drug discovery, tissue engineering, disease modeling, and toxicity testing. |
Key Market Dynamics |
Growing prevalence of respiratory diseases Advancements in organ-on-a-chip technology Increasing focus on personalized medicine Rising government support for research Technological advancements in 3D bioprinting |
Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Lung In-vitro Model Market reached a valuation of approximately 0.58 billion USD in 2023.
The Global Lung In-vitro Model Market is projected to exhibit a CAGR of 17.72% during the forecast period from 2024 to 2032.
North America is expected to dominate the Global Lung In-vitro Model Market throughout the forecast period.
Lung In-vitro Models are primarily used in drug discovery and development, toxicology studies, and basic research.
Some of the major competitors in the Global Lung In-vitro Model Market include Emulate, Inc., InSphero AG, and Mimetas.
The growing demand for personalized medicine, advancements in 3D cell culture techniques, and increasing government funding for lung research are key factors driving market growth.
Challenges faced by the market include the high cost of 3D cell culture systems, the need for standardization of protocols, and the lack of trained personnel.
The Global Lung In-vitro Model Market is projected to reach a valuation of approximately 2.5 billion USD by 2032.
Major trends shaping the market include the integration of artificial intelligence (AI) and machine learning (ML), the development of organ-on-a-chip systems, and the increasing use of patient-derived cells.
Potential applications of Lung In-vitro Models include personalized medicine, disease modeling, and regenerative medicine.